117 related articles for article (PubMed ID: 31733115)
1. Is there a role played by HLA-E, if any, in HPV immune evasion?
Franciosi JR; Gelmini GF; Roxo VS; de Carvalho NS; Bicalho MDG
Scand J Immunol; 2020 Mar; 91(3):e12850. PubMed ID: 31733115
[TBL] [Abstract][Full Text] [Related]
2. Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia.
Kawase K; Taguchi A; Ishizaka A; Lin J; Ueno T; Yoshimoto D; Eguchi S; Mori S; Sone K; Mori M; Yonekura S; Hanazawa T; Maeda D; Kukimoto I; Mano H; Osuga Y; Kawana K; Kawazu M
HLA; 2024 Jun; 103(6):e15509. PubMed ID: 38837741
[TBL] [Abstract][Full Text] [Related]
3. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer.
Sasagawa T; Takagi H; Makinoda S
J Infect Chemother; 2012 Dec; 18(6):807-15. PubMed ID: 23117294
[TBL] [Abstract][Full Text] [Related]
4. HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection.
Glew SS; Connor ME; Snijders PJ; Stanbridge CM; Buckley CH; Walboomers JM; Meijer CJ; Stern PL
Eur J Cancer; 1993; 29A(14):1963-70. PubMed ID: 8280490
[TBL] [Abstract][Full Text] [Related]
5. HLA and susceptibility to cervical neoplasia.
Krul EJ; Schipper RF; Schreuder GM; Fleuren GJ; Kenter GG; Melief CJ
Hum Immunol; 1999 Apr; 60(4):337-42. PubMed ID: 10363725
[TBL] [Abstract][Full Text] [Related]
6. hrHPV E5 oncoprotein: immune evasion and related immunotherapies.
de Freitas AC; de Oliveira THA; Barros MR; Venuti A
J Exp Clin Cancer Res; 2017 May; 36(1):71. PubMed ID: 28545552
[TBL] [Abstract][Full Text] [Related]
7. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
8. Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence.
Ferguson R; Ramanakumar AV; Richardson H; Tellier PP; Coutlée F; Franco EL; Roger M
Hum Immunol; 2011 Apr; 72(4):337-41. PubMed ID: 21256910
[TBL] [Abstract][Full Text] [Related]
9. Immunity to oncogenic human papillomaviruses.
Konya J; Dillner J
Adv Cancer Res; 2001; 82():205-38. PubMed ID: 11447764
[TBL] [Abstract][Full Text] [Related]
10. Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri.
Beskow AH; Gyllensten UB
Int J Cancer; 2002 Oct; 101(6):526-31. PubMed ID: 12237892
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States.
Hildesheim A; Schiffman M; Scott DR; Marti D; Kissner T; Sherman ME; Glass AG; Manos MM; Lorincz AT; Kurman RJ; Buckland J; Rush BB; Carrington M
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1035-41. PubMed ID: 9829713
[TBL] [Abstract][Full Text] [Related]
12. Multiple mechanisms underlie HLA dysregulation in cervical cancer.
Brady CS; Bartholomew JS; Burt DJ; Duggan-Keen MF; Glenville S; Telford N; Little AM; Davidson JA; Jimenez P; Ruiz-Cabello F; Garrido F; Stern PL
Tissue Antigens; 2000 May; 55(5):401-11. PubMed ID: 10885560
[TBL] [Abstract][Full Text] [Related]
13. Immune evasion mechanisms of human papillomavirus: An update.
Steinbach A; Riemer AB
Int J Cancer; 2018 Jan; 142(2):224-229. PubMed ID: 28865151
[TBL] [Abstract][Full Text] [Related]
14. HLA-DRB1*1602 allele is positively associated with HPV cervical infection in Bolivian Andean women.
Cervantes J; Lema C; Valentina Hurtado L; Andrade R; Hurtado Gomez L; Torrico L; Zegarra L; Quiroga G; Asturizaga D; Dulon A; Prada R; Panoso W; Yashiki S; Fujiyoshi T; Sonoda S
Hum Immunol; 2003 Sep; 64(9):890-5. PubMed ID: 12941545
[TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigens I and II haplotypes associated with human papillomavirus 16-positive invasive cervical cancer in Mexican women.
Hernández-Hernández DM; Cerda-Flores RM; Juárez-Cedillo T; Granados-Arriola J; Vargas-Alarcón G; Apresa-García T; Alvarado-Cabrero I; García-Carrancá A; Salcedo-Vargas M; Mohar-Betancourt A
Int J Gynecol Cancer; 2009 Aug; 19(6):1099-106. PubMed ID: 19820376
[TBL] [Abstract][Full Text] [Related]
16. [Papillomavirus infections and cervical tumorigenesis].
Kiyono T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):227-31. PubMed ID: 20235389
[No Abstract] [Full Text] [Related]
17. HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer.
de Araujo Souza PS; Sichero L; Maciag PC
Future Oncol; 2009 Apr; 5(3):359-70. PubMed ID: 19374542
[TBL] [Abstract][Full Text] [Related]
18. The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis.
Xu HH; Yan WH; Lin A
Front Immunol; 2020; 11():1349. PubMed ID: 32670296
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14.
Cicchini L; Westrich JA; Xu T; Vermeer DW; Berger JN; Clambey ET; Lee D; Song JI; Lambert PF; Greer RO; Lee JH; Pyeon D
mBio; 2016 May; 7(3):. PubMed ID: 27143385
[TBL] [Abstract][Full Text] [Related]
20. Altered HLA class I and HLA-G expression is associated with IL-10 expression in patients with cervical cancer.
Rodríguez JA; Galeano L; Palacios DM; Gómez C; Serrano ML; Bravo MM; Combita AL
Pathobiology; 2012; 79(2):72-83. PubMed ID: 22213066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
